Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Aurinia Pharmaceuticals
AUPH
Aurinia Pharmaceuticals
Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$9.00
34.8% overvalued
intrinsic discount
25 Aug
US$12.14
1Y
80.8%
7D
-0.7%
Loading
1Y
80.8%
7D
-0.7%
Author's Valuation
US$9.0
34.8% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$9.0
34.8% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-156m
343m
2014
2017
2020
2023
2025
2026
2028
Revenue US$343.1m
Earnings US$85.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.91%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.45%
Calculation
US$85.77m
Earnings '28
x
13.29x
PE Ratio '28
=
US$1.14b
Market Cap '28
US$1.14b
Market Cap '28
/
105.88m
No. shares '28
=
US$10.77
Share Price '28
US$10.77
Share Price '28
Discounted to 2025 @ 6.45% p.a.
=
US$8.93
Fair Value '25
